Association between visual functioning and death in AMD

Article

Researchers investigated the relationship between visual functioning measured using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of AMD.

Laughing seniors sitting together playing a card game (Adobe Stock / pressmaster)

Multivariable analysis showed that for each 10-point increase in a patient’s VFQ-25 scores for general health and driving, the risk of death decreased with a hazard ratio of 0.85 (95% confidence intervals (CIs): 0.80, 0.91, P<0.0001) and 0.92 (95% CI: 0.87, 0.97, P=0.005), respectively. (Adobe Stock / pressmaster)

Sophie E. Smith, BA, and colleagues from the Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, examined a population of patients with age-related macular degeneration (AMD) and reported that better general health and ability to drive were each separately associated with a lower risk of death.1

In this observational cohort study conducted in patients from July 9, 2014, to December 31, 2021, the researchers investigated the relationship between visual functioning measured using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of AMD.

The AMD stages were classified as follows: early AMD, intermediate AMD, geographic atrophy (GA), neovascular AMD (NV), or both advanced types of AMD (NV and GA both present).

The main outcome measures were the all-cause mortality statistics obtained through a collaborative agreement with the Colorado Department of Public Health and Environment. The investigators compared the death rates through October 19, 2022, by demographics and potential confounders.

The patient cohort included 876 patients, of whom 180 (20.6%) died during the follow-up period (average, 52.5 months).

Univariate analysis showed that the composite VFQ-25 score and all subscale scores except for ocular pain were correlated significantly with time to mortality. Additionally, age, AMD category, marital status, history of smoking, and multiple chronic comorbid conditions were associated significantly with time to mortality.

Multivariable analysis showed that for each 10-point increase in a patient’s VFQ-25 scores for general health and driving, the risk of death decreased with a hazard ratio of 0.85 (95% confidence intervals (CIs): 0.80, 0.91, P<0.0001) and 0.92 (95% CI: 0.87, 0.97, P=0.005), respectively. Composite and other subscale scores were not significantly associated with mortality after adjusting for confounding variables, the authors reported.

“This cohort of patients with AMD had a 20% rate of death in the 52.5-month average follow-up time,” investigators said. “Better general health and ability to drive, as measured by the VFQ-25, were each separately associated with significantly lower risk of death among individuals with AMD.”

Reference
1. Smith SE, Lynch AM, Auer E, et al. Visual Functioning and Mortality of Age-Related Macular Degeneration Patients in a Colorado Cohort. Investigative Ophthalmology & Visual Science. 2023;64(8):1752-1752. Accessed July 10, 2023. https://iovs.arvojournals.org/article.aspx?articleid=2790146
Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
© 2024 MJH Life Sciences

All rights reserved.